NanoFuse Biologics Announces Leadership Changes After Merger with NANISX

In August, KICVentures Group merged its holdings in NanoFUSE Biologics, InSpan and Sacrix into NANISX, a new spine company which will be divided into two ASC divisions.
 
NanoFUSE is positioning to build a dedicated team, expand its market share of the over $5 billion orthobiologics market, and challenge Stryker’s Vitoss BA bioactive glass, the top-selling synthetic biologic. This goal made it compelling for NanoFUSE to decide to merge with NANISX LLC and prepare for an IPO to raise capital as a combined offering with InSpan and Sacrix as complimentary products with large total addressable markets across Interventional Pain Management (IPM), Orthopedic surgeons and Neurosurgeons.
 
“NanoFUSE Biologics is unique in having its own patented manufacturing process for its micro-spherical fiber-based bioactive glass that can be shaped into any formulation for various applications in spine surgery, orthopedics, dental and craniofacial surgery,” says board-certified orthopedic spine surgeon and CEO and founder of KICVentures Group, Dr. Kingsley R. Chin.
 
Following the merger with Nanisx, Chin will step down as CEO of NanoFuse Biologics.
 
“NanoFUSE Biologics has been showing steady organic revenue growth since being acquired by the KICVentures Group in 2018 and is poised for accelerated commercialization as more doctors adopt InSpan and Sacrix in ASCs and pull-through NanoFUSE as a compliment to the devices,” says CFO, Aditya Humad.
 
Bioactive glass is going to be a significant factor in the future of synthetic biologics with its flexible forms and effectiveness. NANISX technology platform has been revenue and EBITDA positive and should grow rapidly with the expected addition of a new chief executive officer to be announced soon.
 
The company has initiated the listing process to prepare for an IPO with a New York-based advisory firm including the search for the right governance to establish processes to scale and be ready within 12 to 18 months.